Combination & Conjugate Vaccines

Increasingly, more diseases are becoming vaccine preventable, but maintaining community and provider acceptance demands that the number of injections doesn’t increase. Combination conjugate vaccines represent an inevitable and important advance. This paper reviews the efficacy and safety of combination conjugate vaccines, including immunological mechanisms underlying interactions among vaccine epitopes, the role of immunological memory, and correlates of immunity. Specific attention is given to the experience with combination vaccines against each of Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis. The implications of these findings for different communities are discussed, key areas for further research identified and implications for post-licensure monitoring addressed.

  • BCG vaccines
  • Dtap, Tdap vaccines
  • MMR (Measles, Mumps, and Rubella) vaccines
  • MMR (Measles, Mumps, and Rubella) vaccines
  • Diphtheria and tetanus toxoids (DT) vaccines
  • Mumps and rubella (Mu-Rub) vaccines
  • Formulation technologies used for conjugated vaccines
  • Peptides, Carbohydrates and Antigens containing vaccines

Related Conference of Combination & Conjugate Vaccines

July 27-28, 2018

31st Annual Congress on Vaccines & Clinical Trials

Vancouver, Canada
October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan

Combination & Conjugate Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in